Neoadjuvant chemotherapy for epithelial ovarian cancer - Role of apoptosis

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 4, 2005, Pages 427-435

  Dutta, Tania ^a   Sharma, Himani ^a   Kumar, Lalit ^b   Dinda, A K ^a   Kumar, Sunesh ^a   Bhatla, Neerja ^a   Singh, Neeta ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Apoptosis; bcl 2; Chemotherapy; Ovarian carcinoma; Survivin and p53

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; PROTEIN P73; SURVIVIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; ASCITES; ASCITES CELL; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CHEMOTHERAPY, ADJUVANT; CYSTEINE PROTEINASE INHIBITORS; FEMALE; GENES, BCL-2; HUMANS; IN SITU NICK-END LABELING; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS;

EID: 23244448021     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0993-9     Document Type: Article

References (23)

1. Pettersson F (1991) Annual report on the results of treatment of gynecologic cancer. Int J Gynecol Obstet 36:238-277
2. Richardson GS, Scully RE, Nikrui N (1985) Common epithelial cancer of the ovary. N Engl J Med 312:415-424
3. Natarajan M, Saravanan SM, Elson DL (2003) Advanced ovarian carcinoma as a chronic disease: a case report and review. S D J Med 56:515-521
4. See HT, Kavanagh JJ, Hu W, Bast RC (2003) Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 13:701-734
5. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, Humblet Y, Donnez J, Machiels JP (2003) Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90:163-169
6. Gadducci A, Cosio S, Muraca S, Genazzani AR (2002) Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol 23:390-396
7. Strasser A, O'Connor L, Dixit VM (2000) Apoptosis signaling. Annu Rev Biochem 69:217-245
8. Daponte A, Guidozi F, Tiltman AJ, Marineanu A, Taylor L (1999) p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary. Anticancer Res 19:2387-2389
9. Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V (1998) Bel-XL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 70:398-403
10. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K, Nagata I (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 35:1214-1219
11. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134
12. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412
13. Sharma H, Sen S, Mathur M, Bahadur S, Singh N (2004) Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck 26:733-740
14. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F (2000) p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18:3936-3945
15. Gadducci A, Cianci C, Cosio S, Carnino F, Fanucchi A, Buttitta F, Conte PF, Genazzani AR (2000) p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res 20:4793-4799
16. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402
17. Alvarez AA, Lambers AR, Lancaster JM, Maxwell GL, Ali S, Gumbs C, Berchuck A, Futreal PA (2001) Allele loss on chromosome 1p36 in epithelial ovarian cancers. Gynecol Oncol 82:94-98
18. Chen CL, Ip SM, Cheng D, Wong LC, Ngan HY (2000) p73 gene expression in ovarian cancer tissues and cell lines. Clin Cancer Res 6:3910-3915
19. Codegoni AM, Bertoni F, Patregnani C, Marinetti E, D'Incalci M, Broggini M (1999) Allelic expression of p73 in human ovarian cancers. Ann Oncol 10:949-953
20. Kassim SK, Ali HS, Sallam MM, Fayed ST, Seada LS, abd-Elkawy E, Seada MA, Khalifa A (1999) Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem 32:333-338
21. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR (2000) BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 82:436-440
22. Altieri DC (2003) Survivin and apoptosis control. Adv Cancer Res 88:31-52
23. Bhalla KN (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086